Early Detection Research Network Translating Biomarkers 早期检测的生物标志物研究网络翻译.pptVIP

EDRN BIOMARKER DEVELOPMENT Sam Hanash Fred Hutchinson Cancer Research Center CONTENTS 1- Two studies that progressed from discovery to blinded validation in a context of early detection 2- Collaborative work within and outside of EDRN Development laboratories 3- Leveraging resources outside of EDRN Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancerSandra R. Pereira-Faca et al (Cancer Research ‘07) Validation Phase 2 - Validate intended clinical application: Blood test in combination with CT scanning - Demonstrate increased specificity and sensitivity of CT scans when combined with an autoantibody marker panel for high risk subjects - Retrospective component - Prospective component Pancreatic cancer mouse model Validation 54 potential biomarkers  NHLBI-NCI-WHI-EDRN Collaborative study  S. Hanash R. Prentice  Co-PIs 100 colon cancer cases that occurred 6 – 18 m following yr 3 blood draw + 100 matched controls 10 teams applied a variety of proteomics approaches to aliquots from the same blood draws All data compared and integrated Promising biomarkers to be validated in a second phase Participating Institutions Fred Hutchinson Cancer Research Center Harvard Medical School R. Kucherlapati PNNL R. Smith Johns Hopkins University D, Chan Northeastern University W. Hancock University of Michigan A. Chinnaiyan Wayne State University M. Tainsky Eastern Virginia University J. Semmes Wistar Institute D. Speicher University of Pittsburgh W. Bigbee Innovative nature of the study Discovery studies at the pre-clinical stage Reduced bias due to multi-institutional sample collection Reduced bias due to asymptomatic status of subjects at the time of blood draw Analysis